The Effect of Liver Disease on Hepatic Microenvironment and Implications for Immune Therapy

Overview

Journal Front Pharmacol

Date 2023 Aug 23

PMID 37608898

Authors

Zachary J Brown

Samantha M Ruff

Timothy M Pawlik

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth leading cause of cancer-related death worldwide. HCC often occurs in the setting of chronic liver disease or cirrhosis. Recent evidence has highlighted the importance of the immune microenvironment in the development and progression of HCC, as well as its role in the potential response to therapy. Liver disease such as viral hepatitis, alcohol induced liver disease, and non-alcoholic fatty liver disease is a major risk factor for the development of HCC and has been demonstrated to alter the immune microenvironment. Alterations in the immune microenvironment may markedly influence the response to different therapeutic strategies. As such, research has focused on understanding the complex relationship among tumor cells, immune cells, and the surrounding liver parenchyma to treat HCC more effectively. We herein review the immune microenvironment, as well as the relative effect of liver disease on the immune microenvironment. In addition, we review how changes in the immune microenvironment can lead to therapeutic resistance, as well as highlight future strategies aimed at developing the next-generation of therapies for HCC.

Citing Articles

HOXB4/METTL7B cascade mediates malignant phenotypes of hepatocellular carcinoma through TKT m6A modification.

Guo E, Li L, Yang J, Zhou Y, Bai L, Zhu W Biol Direct. 2025; 20(1):26.

PMID: 40045399 PMC: 11884015. DOI: 10.1186/s13062-025-00620-3.

Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Lee J, Yoo J, Kim J, Lee D, Yang K, Kim B Front Immunol. 2024; 15:1506355.

PMID: 39720711 PMC: 11666515. DOI: 10.3389/fimmu.2024.1506355.

Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma.

Anbarasu C, Williams-Perez S, Camp E, Erstad D Cancers (Basel). 2024; 16(16).

PMID: 39199546 PMC: 11352989. DOI: 10.3390/cancers16162773.

A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.

Zheng Z, Mei J, Guan R, Zhang J, Xiong X, Gan J Cancer Immunol Immunother. 2024; 73(8):158.

PMID: 38834790 PMC: 11150358. DOI: 10.1007/s00262-024-03713-6.

Neoadjuvant systemic therapy for hepatocellular carcinoma.

Chick R, Ruff S, Pawlik T Front Immunol. 2024; 15:1355812.

PMID: 38495884 PMC: 10940409. DOI: 10.3389/fimmu.2024.1355812.

References

Lefebvre E, Moyle G, Reshef R, Richman L, Thompson M, Hong F . Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016; 11(6):e0158156. PMC: 4922569. DOI: 10.1371/journal.pone.0158156. View

Singal A, Kamath P, Gores G, Shah V . Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol. 2013; 12(4):555-64. PMC: 3883924. DOI: 10.1016/j.cgh.2013.06.013. View

Lim C, Lee Y, Pan L, Lai L, Chua C, Wasser M . Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2018; 68(5):916-927. DOI: 10.1136/gutjnl-2018-316510. View

Yao F, Mehta N, Flemming J, Dodge J, Hameed B, Fix O . Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015; 61(6):1968-77. PMC: 4809192. DOI: 10.1002/hep.27752. View

Obstfeld A, Sugaru E, Thearle M, Francisco A, Gayet C, Ginsberg H . C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 2010; 59(4):916-25. PMC: 2844839. DOI: 10.2337/db09-1403. View

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

Prieto J, Melero I, Sangro B . Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015; 12(12):681-700. DOI: 10.1038/nrgastro.2015.173. View

Heinrich B, Brown Z, Diggs L, Vormehr M, Ma C, Subramanyam V . Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology. 2020; 160(1):331-345.e6. PMC: 7755834. DOI: 10.1053/j.gastro.2020.09.031. View

Chen R, Xu L, Du S, Huang S, Wu H, Dong J . Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding. Toxicol Lett. 2015; 241:103-10. DOI: 10.1016/j.toxlet.2015.11.019. View

10.

Li W, Han J, Wu H . Regulatory T-cells promote hepatitis B virus infection and hepatocellular carcinoma progression. Chronic Dis Transl Med. 2017; 2(2):67-80. PMC: 5643754. DOI: 10.1016/j.cdtm.2016.09.001. View

11.

De Lorenzo S, Tovoli F, Trevisani F . Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2022; 14(19). PMC: 9564277. DOI: 10.3390/cancers14194616. View

12.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

13.

Rensen S, Slaats Y, Nijhuis J, Jans A, Bieghs V, Driessen A . Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol. 2009; 175(4):1473-82. PMC: 2751544. DOI: 10.2353/ajpath.2009.080999. View

14.

Yau T, Park J, Finn R, Cheng A, Mathurin P, Edeline J . Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2021; 23(1):77-90. DOI: 10.1016/S1470-2045(21)00604-5. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Maluccio M, Covey A, Gandhi R, Gonen M, Getrajdman G, Brody L . Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005; 16(7):955-61. DOI: 10.1097/01.RVI.0000161377.33557.20. View

17.

Feng M, Zhang J, Anver M, Hassan R, Ho M . In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer. 2011; 2:123-31. PMC: 3072618. DOI: 10.7150/jca.2.123. View

18.

Van Allen E, Miao D, Schilling B, Shukla S, Blank C, Zimmer L . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-211. PMC: 5054517. DOI: 10.1126/science.aad0095. View

19.

Brandt E, Baues M, Wirtz T, May J, Fischer P, Beckers A . Chemokine CXCL10 Modulates the Tumor Microenvironment of Fibrosis-Associated Hepatocellular Carcinoma. Int J Mol Sci. 2022; 23(15). PMC: 9329882. DOI: 10.3390/ijms23158112. View

20.

Arrese M, Cabrera D, Kalergis A, Feldstein A . Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci. 2016; 61(5):1294-303. PMC: 4948286. DOI: 10.1007/s10620-016-4049-x. View